Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 67Breast 41Plasma cell 19Lymphoid 14Sarcoma 5Other hematologic neoplasm 5Tumor-Agnostic 4Genitourinary 4Dermatologic 4Other solid neoplasm 3Thoracic 2NET 1Head & Neck 1Gastrointestinal 1Endocrine 1Classical hematology 1CNS 1

Conditions

Glioblastoma 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 64Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × liposomal doxorubicin × CNS × Clear all
NCT00944801 2009-07-23

Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma

University of Regensburg

Phase 1/2 Completed
63 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡